Table 1 Characteristics of the study population (N = 68)
Characteristics | Total |
|---|---|
Age at KP (days) | 62.5 ± 21.3 |
Female (%) | 45 (66.2%) |
AST (U/L) | 181 (132–310) |
ALT (U/L) | 112 (75–160) |
GGT (U/L) | 397 (242–639) |
ALP (U/L) | 594.2 ± 207.9 |
TB (µmol/L) | 177.1 ± 48.6 |
DB (µmol/L) | 138.0 ± 40.0 |
TBA (µmol/L) | 112 (92–138) |
Albumin (g/L) | 39.5 (37.4–42.4) |
Platelet (cells/L) | 418 ± 150 |
APRI | 1.46 (0.74–2.67) |
iBALF | 4.04 (3.33–4.56) |
Ishak (stage) | 4 (3–5) |
Metavir (stage) | 3 (2–4) |
BA-specific (stage) | 3 (2–3) |
Portal inflammation (grade) | 2 (2–3) |
Intrahepatic cholestasis (grade) | 2 (1–3) |
Ductal proliferation (grade) | 2 (2–3) |
Jaundice clearance (%) | 23 (33.8%) |
Cholangitis (%) | 43 (61.4%) |
Follow up (months) | 13 (5–20) |
1-year native liver survival (%) | 60.6% |